Murray Stewart

Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial

Adrian F. Hernandez, Jennifer B. Green, Salim Janmohamed et al. · The Lancet · 2018 · 1.7K citations · Full text

Diabetes Management, Cardiovascular Disease, Diabetes +6

Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study

Richard E. Pratley, Michael A. Nauck, Anthony Barnett et al. · The Lancet Diabetes & Endocrinology · 2014 · 319 citations

Diabetes Management, Harmony 7, Medicine +6

Potential of Albiglutide, a Long-Acting GLP-1 Receptor Agonist, in Type 2 Diabetes

Julio Rosenstock, Jane E.B. Reusch, Mark Bush et al. · Diabetes Care · 2009 · 233 citations · Full text

HARMONY 3: 104-Week Randomized, Double-Blind, Placebo- and Active-Controlled Trial Assessing the Efficacy and Safety of Albiglutide Compared With Placebo, Sitagliptin, and Glimepiride in Patients With Type 2 Diabetes Taking Metformin

Bo Åhrén, Susan Johnson, Murray Stewart et al. · Diabetes Care · 2014 · 222 citations

Advancing Basal Insulin Replacement in Type 2 Diabetes Inadequately Controlled With Insulin Glargine Plus Oral Agents: A Comparison of Adding Albiglutide, a Weekly GLP-1 Receptor Agonist, Versus Thrice-Daily Prandial Insulin Lispro

Julio Rosenstock, Vivian Fonseca, Jorge Luiz Gross et al. · Diabetes Care · 2014 · 202 citations